Skip to main content
. 2019 Nov 1;26(13):1719–1728. doi: 10.1177/1352458519881759

Figure 1.

Figure 1.

Proportions of early relapsers and early non-relapsers. Proportions of patients with and without relapse between alemtuzumab Courses 1 and 2 in the core CARE-MS I (left) and CARE-MS II (right) studies.

CARE-MS: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis.